Welcome to our dedicated page for Chemomab Therapeutics news (Ticker: CMMB), a resource for investors and traders seeking the latest updates and insights on Chemomab Therapeutics stock.
Chemomab Therapeutics Ltd. reports developments for its clinical-stage biotechnology program in fibro-inflammatory diseases. Recurring updates center on nebokitug, an antibody targeting CCL24, and its clinical evaluation in primary sclerosing cholangitis through the SPRING trial, related open-label extension data, biomarker findings, macrophage-mediated mechanism research, and peer-reviewed or medical-meeting presentations.
Company news also covers financial results, corporate updates, regulatory interactions with agencies, preparations for later-stage development, strategic partnering discussions, capital-raising activity involving American Depositary Shares, and participation in healthcare and rare-disease investor conferences.
Chemomab Therapeutics, Ltd. (NASDAQ: CMMB) has expanded its partnership with AGC Biologics for the manufacturing of CM-101, a Phase II investigational drug targeting fibrosis-related diseases like Primary Sclerosing Cholangitis and Systemic Sclerosis. The agreement aims to optimize and upscale the manufacturing process for upcoming pivotal studies, with clinical trial materials produced in Copenhagen. CM-101 has shown promise in clinical trials, and the collaboration is expected to enhance manufacturing capabilities ahead of Phase 3 trials.
Chemomab Therapeutics (Nasdaq: CMMB) has announced a poster presentation at the International Liver Congress 2021 from June 23-26, 2021. Dr. Arnon Aharon will present findings related to the role of CCL24 in bile duct fibrosis in primary sclerosing cholangitis (PSC). This presentation, titled The peri-ductular CCL24 rich niche promotes bile duct fibrosis related liver damage in primary sclerosing cholangitis, highlights CCL24's significance in fibrosis-related diseases. Full poster access will be available on Chemomab's website post-event.
Chemomab Therapeutics Ltd (Nasdaq: CMMB) reported positive financial and operational results for Q1 2021, with a cash position of $58.2 million following a $45 million private placement. Key highlights include positive Phase Ib data for CM-101 in nonalcoholic fatty liver disease (NAFLD) and the initiation of Phase IIa trials for both primary sclerosing cholangitis (PSC) and nonalcoholic steatohepatitis (NASH). The company plans to start an additional Phase II trial for Systemic Sclerosis (SSc) by year-end 2021. Net loss remained stable at $1.7 million for the quarter.
Chemomab Therapeutics Ltd (Nasdaq: CMMB) announced its CEO, Dr. Adi Mor, will present a corporate update at the Oppenheimer Virtual Rare and Orphan Disease Summit on May 21, 2021.
The event aims to share insights on Chemomab's innovative therapeutics targeting fibrosis-related diseases, particularly its monoclonal antibody CM-101, which is in clinical development for orphan diseases like Primary Sclerosing Cholangitis (PSC) and Systemic Sclerosis (SSc).
The presentation will be available online for 30 days following the event.
Chemomab Therapeutics (Nasdaq: CMMB) has started enrollment for its Phase 2a study of CM-101 aimed at treating Non-Alcoholic Steatohepatitis (NASH). CM-101, a humanized monoclonal antibody, targets CCL24 to mitigate inflammation and fibrosis. The randomized, double-blind trial will involve 40 patients and aims to evaluate CM-101's safety and anti-fibrotic effects, with results expected in the first half of 2022. This study is part of Chemomab’s broader clinical strategy, which includes ongoing trials for other fibrosis-related conditions.
Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) has appointed four new members to its Board of Directors, including Dr. Alan Moses, Dr. Claude Nicaise, Mr. Joel Maryles, and Mr. Neil Cohen. This strategic move aims to enhance clinical and regulatory expertise as the company progresses its proof-of-concept trials for CM-101, a therapeutic targeting fibrosis-related diseases. Additionally, Chemomab successfully completed a PIPE financing round, raising $45.5 million, with approximately 11.9 million ADSs outstanding on a fully diluted basis.
The Genesis Prize Foundation announced that Stan Polovets has stepped down as chairman of Anchiano Therapeutics following its merger with Chemomab Therapeutics on March 16, now trading as CMMB. During Polovets' tenure, Anchiano's stock surged 630%, outperforming many peers. The merger aims to focus on innovative therapies for inflammation and fibrosis, backed by significant investor financing. Polovets expressed gratitude for the management team's efforts, highlighting the company’s potential for further success in the biotech space.